A U.S. jury found that Parse Biosciences, a subsidiary of Qiagen, willfully infringed three patents tied to Scale Biosciences technology—acquired by 10x Genomics in 2025—while also upholding patent validity. Damages awarded exceeded $4.8 million based on a royalty model for Parse Evercode whole transcriptome sales from February 2021 through June 30, 2026. The verdict could reshape competitive dynamics in single-cell whole-transcriptome workflows in the U.S., with 10x seeking enhanced damages, attorney’s fees, and a permanent injunction to stop further infringement.